Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study

This publication has 18 references indexed in Scilit:

• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
  The Lancet, 2017
• PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
  Science Translational Medicine, 2016
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
  Nature, 2014
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
  Nature, 2014
• Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
  Clinical Cancer Research, 2012
• PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions
  Mucosal Immunology, 2009
• B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma
  Biochemical and Biophysical Research Communications, 2008
• Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production
  The Journal of Immunology, 2003
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
  Nature Medicine, 2002
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation
  Nature Immunology, 2001